Cancer Drug Coverage and Denials
Plain-language guides to why insurers deny specialty cancer drugs, your appeal rights, and where to get cancer-specific coverage help.
Drug guides
PD-1 immune checkpoint inhibitor. Treats a range of cancers including melanoma, non-small-cell lung cancer, and others.
Opdivo (nivolumab)PD-1 immune checkpoint inhibitor. Treats melanoma, lung, kidney, and other cancers.
Tecentriq (atezolizumab)PD-L1 immune checkpoint inhibitor. Treats lung, bladder, and other cancers.
Revlimid (lenalidomide)immunomodulatory agent. Treats multiple myeloma and certain blood disorders.
Tagrisso (osimertinib)EGFR tyrosine kinase inhibitor. Treats EGFR-mutation-positive non-small-cell lung cancer.
Imbruvica (ibrutinib)BTK inhibitor. Treats certain leukemias and lymphomas.
Ibrance (palbociclib)CDK4/6 inhibitor. Treats HR-positive, HER2-negative breast cancer.
Darzalex (daratumumab)anti-CD38 monoclonal antibody. Treats multiple myeloma.
Verzenio (abemaciclib)CDK4/6 inhibitor. Treats HR-positive, HER2-negative breast cancer.
Xtandi (enzalutamide)androgen receptor inhibitor. Treats prostate cancer.
Cancer-specific resources
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.